Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
about
Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategyLoss of CD4 T-cell-dependent tolerance to proteins with modified amino acidsPolymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?Melanoma genetics and the development of rational therapeutics.High Interleukin 27 Production is Associated with Early Clinical Stage and Localized Disease in Patients with Melanoma.Immunologic functions as prognostic indicators in melanomaOutcome after therapeutic lymph node dissection in patients with unknown primary melanoma siteFocus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaAutoimmunity and tumor immunology: two facets of a probabilistic immune systemGenetic engineering of hematopoietic stem cells to generate invariant natural killer T cellsCTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.Proteomics in melanoma biomarker discovery: great potential, many obstacles.Clinical utility of serum autoantibodies detected by protein microarray in melanomaId1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation.Immunohistochemistry in melanocytic proliferative lesions.Autoantibodies to mesothelin in infertility.Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.Anti-tumor antibodies in ovarian cancer.Immune system versus tumor: shifting the balance in favor of DCs and effective immunitymRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model.Anti-HE4 antibodies in infertile women and women with ovarian cancer.Tumor microenvironment and myeloid-derived suppressor cells.Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells.Malignant Peritoneal Mesothelioma: Characterization of the Inflammatory Response in the Tumor Microenvironment.Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells.Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.Uncarboxylated Osteocalcin Induces Antitumor Immunity against Mouse Melanoma Cell Growth.Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma.T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma.Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.miRNAs, Melanoma and Microenvironment: An Intricate Network.The circadian clock regulates cisplatin-induced toxicity and tumor regression in melanoma mouse and human models.
P2860
Q24814910-ABF32A73-C0A8-40B4-9247-A1D4C4EDC4C9Q28243525-28D581F1-61D2-4BF7-A8F1-155846E398D9Q33492805-B6EE5CC1-3C3E-4BF5-AFC0-0F41097B536AQ33726956-0842FA7B-90DF-4F65-A2E8-DD6EAE587EACQ33801032-2D4F9CC0-C621-4F28-9E98-8B6083F24A64Q33835011-778B2C42-1AFE-4326-BB49-CB7C1E4DD2DEQ33911465-6497F40F-B67D-4AC6-93DE-FA2180F1C830Q34111789-92A1BAE9-1954-4E6D-9C30-5818B52C4873Q34537272-2058DC2C-9A35-4302-A00F-2D5AF7CFA921Q35062758-6A00EE70-924E-435A-BBF6-93F5BEAC8F3CQ35190928-FCB97343-ABAB-4331-A34A-3A59DEEAB497Q35374035-806CBD01-B2FE-4453-802F-7957049FFF83Q35418114-9454FF58-D087-4EFD-962A-16A60F459CEEQ35579455-BC33F9EC-4636-496B-A99B-6461115BE3FBQ35798186-AD0BC0AD-916E-43E6-8820-8C65AE0437B9Q35832948-705014FD-344C-4A00-9350-ECC22CE1D128Q35848463-4F9C8781-D3DE-4257-9BB7-1F5A2E649228Q36232263-51EC6CF5-9927-45B0-AEB9-2FB3CD97AB74Q36441605-21C1A7D2-7615-45FC-A67F-6F120B098D81Q37079145-6CA229B1-F3C8-42AE-8D53-BCD621746FBCQ37107033-352AB980-58AC-48AB-B073-61CBAB7729C5Q38067642-45F83F10-9071-4A7C-9181-AFEB3112C007Q38096466-8AFBABF0-3386-424A-8882-6FECADAE87EEQ38945362-211A88B1-6A2C-47FC-BE23-1EFD1346D796Q40314772-E95F96D5-9F62-4412-937D-A43DB691CC66Q40428099-2C2D5627-8681-4F15-9DBE-6E0139B19EF3Q41243255-EAB67AB7-58EC-45CE-A1C0-DBB082C29ECAQ42112527-F6DC3612-3D8B-4A07-8CAE-60F9C47A95CFQ43089933-7AB7D53D-37DF-4C1F-BEC3-58B3F1308F6AQ47134263-A62E2A45-52C2-4ECA-927D-57DCC0B51DF2Q47152593-6BBFA4F2-1152-4D01-95D0-3E942DB03D5DQ55318141-C8CCBA2C-1041-46F9-9348-4700CBC99CB3
P2860
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
@ast
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
@en
type
label
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
@ast
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
@en
prefLabel
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
@ast
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
@en
P2093
P2860
P356
P1433
P1476
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
@en
P2093
Alan N Houghton
Jedd D Wolchok
José A Guevara-Patino
Mary Jo Turk
Teresa Ramirez-Montagut
P2860
P2888
P304
P356
10.1038/SJ.ONC.1206462
P407
P577
2003-05-01T00:00:00Z
P5875
P6179
1020413059